Samsung Biologics declares PolyPeptide tender offer successful
An additional acceptance period runs October 19 to 30, with settlement now expected late 2026 or in the first quarter of 2027.
TR
By Tom Reyes · Markets Editor
Oct 16 01:00 ETSource: TradingView
The wire
- 01Samsung Biologics, through subsidiary Samsung Peptide AG, published the definitive interim result of its offer for PolyPeptide Group shares and declared it successful, subject to remaining conditions including regulatory clearances.
- 02PolyPeptide is a major contract manufacturer of peptide APIs, so ownership change bears on supply arrangements for peptide drug developers.
- 03An extraordinary general meeting is set for October 26 to lift transfer restrictions and elect Samsung nominees; Samsung Peptide intends a squeeze-out and SIX delisting after settlement.
From the source
Read at tradingview.comPolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
